Tag: Gip glp 1 agonists

Clinical trials show that individuals on tirzepatide (Zepbound, Mounjaro) can achieve significant fat mass reduction, but many wonder: precisely where does the fat go on tirzepatide?. The answer lies in a powerful biological process where stored fat is converted into energy and harmlessly eliminated from the body.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, begins working almost immediately after an injection, though noticeable effects on appetite and weight loss unfold over several weeks and months. Its gradual action is supported by a half-life of approximately 5 days, which allows for once-weekly dosing and steady medication levels. Understanding this timeline is crucial for setting realistic expectations for treatment.